All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine partners with Merck to develop companion diagnostics
Precision Medicine
Jun 5, 2023
This week:
Funding
PuppyGraph raises USD 5 million in seed funding to expand product development
Data Infrastructure & Analytics
Nov 8, 2024
Product updates
FedEx opens automated facility at Memphis World Hub
Logistics Tech
Nov 8, 2024
Product updates
Formlabs launches Creator Series resins for 3D printers at Formnext 2024
Additive Manufacturing
Nov 7, 2024
Product updates
3D Systems launches PSLA 270 printer and post-processing solutions
Additive Manufacturing
Nov 7, 2024
Product updates
Caracol launches Vipra AM metal 3D printing platform
Additive Manufacturing
Nov 7, 2024
Partnerships
ICEYE partners with Carahsoft to provide SAR satellite data to US government agencies
Next-gen Satellites
Nov 7, 2024
M&A
BlackSky acquires remaining 50% stake in LeoStella
Next-gen Satellites
Nov 7, 2024
Partnerships
GenomOncology partners with Genomenon to streamline germline variant classification and reporting
Precision Medicine
Nov 7, 2024
Partnerships
Concr partners with CariGenetics to improve precision medicine with AI and diverse data
Precision Medicine
Nov 7, 2024
Partnerships
Concr partners with CariGenetics to improve precision medicine with AI and diverse data
AI Drug Discovery
Nov 7, 2024
Precision Medicine

Precision Medicine

Jun 5, 2023

Foundation Medicine partners with Merck to develop companion diagnostics

Partnerships

  • Companion diagnostics developer Foundation Medicine has entered a strategic collaboration with multinational pharmaceutical company Merck KGaA, Germany, to develop companion diagnostics using FoundationOne CDx and FoundationOne Liquid CDx for selected cancer treatments in the US market. This is an extension of their previous partnership focused on data solutions, which was established in 2020.

  • The partnership aims to leverage Foundation Medicine's comprehensive genomic profiling tests to identify patients with genomic alterations that may benefit from specific targeted therapies. The collaboration will support the development of personalized treatment options for cancer patients by using molecular profiling to guide treatment decisions and optimize therapy development. This will enable oncologists to use FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to identify eligible patients for targeted therapies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.